Q363 · Department of Health inspectors identified…

Q363 · Category H: Licensed operations and routine regulatory oversight (Q351–Q400)

At the end of the Department of Health inspection, the inspectors will hold a debriefing meeting with the company’s management and verbally advise them of the preliminary major deficiencies identified. You will subsequently receive a formal inspection report listing all observed deficiencies in writing and classifying them according to their severity (for example, critical, major and other deficiencies). The report will require you to submit a detailed corrective and preventive action plan (CAPA Plan) for each deficiency within a specified period (usually 30 days). The plan must explain how you will correct the current problem (corrective action) and what systematic measures you will take to prevent it from recurring (preventive action). The Department of Health will review your CAPA Plan and, if it considers the plan feasible, require you to implement it. It may follow up on your remediation through document reviews or a further site inspection.

📘 Regulatory basis

The Department of Health’s inspection and follow-up procedures form part of its supervisory duties as a regulatory authority under the Pharmacy and Poisons Ordinance (Cap. 138), and are intended to ensure the ongoing compliance of licence holders.

📗 Drew Tang's recommendations

Do not panic after receiving an inspection report. Immediately establish a dedicated team to analyse the root cause of every deficiency carefully. When preparing a CAPA plan, make it specific and feasible, and set clear completion dates and responsible persons. A high-quality CAPA plan not only resolves the immediate issues but also demonstrates your company’s proactive and professional approach to compliance to the Department of Health. If you have questions about preparing an effective CAPA plan, Rengangyongsheng (Hong Kong) Limited’s experts can provide guidance.

📕 Risk notice

Failure to submit a CAPA plan on time, or submitting a superficial plan lacking substance, will be regarded as disregard for regulatory requirements. If a “critical deficiency” is identified, such as data falsification or a direct threat to public health, the Department of Health may take immediate action, including requiring a product recall, suspending production or distribution, or even considering revocation of the licence.

Plan Your Hong Kong Pharmaceutical Licensing Project with Drew Tang

Business Manager Tang Shangyong (Drew Tang) will review your products, operating model, licence type and preparation requirements with you one-to-one. The precise service scope is confirmed in writing; pharmaceutical duties are carried out by legally qualified personnel, and approvals are determined by the competent authorities.

Department of Health inspectors identified some deficiencies during the inspection. What happens next?

Plan Your Hong Kong Pharmaceutical Licensing Project with Drew Tang